Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

摘要

The current study was conducted to evaluate the effects of 2 different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome (PCOS). This randomized double-blind, placebo-controlled trial was performed on 90 insulin-resistant patients with PCOS according to the Rotterdam criteria aged 18-40 years old. Participants were randomly allocated into 3 groups to receive either 4 000 IU of vitamin D (n = 30) or 1 000 IU of vitamin D (n = 30) or placebo (n = 30) per day for 12 weeks. Vitamin D supplementation (4 000 IU), compared with vitamin D (1 000 IU) and placebo, led to reduced fasting plasma glucose (-4.3 +/- 8.6 vs. -4.7 +/- 7.1 and +0.1 +/- 6.7 mg/dl, respectively, p = 0.02), serum insulin concentrations (-2.7 +/- 2.7 vs. -1.4 +/- 4.2 and -0.1 +/- 4.1 mu IU/ml, respectively, p = 0.02), and HOMA-IR (-0.6 +/- 0.6 vs. -0.4 +/- 1.0 and -0.1 +/- 0.9, respectively, p = 0.02). In addition, we found significant decreases in mean change of serum triglycerides (-10.3 +/- 7.3 vs. -3.6 +/- 14.5 and + 6.9 +/- 23.8 mg/dl, respectively, p = 0.001), VLDL-(-2.0 +/- 1.5 vs. -0.7 +/- 2.9 and + 1.4 +/- 4.8 mg/dl, respectively, p = 0.001), total-(-14.0 +/- 9.5 vs. -6.2 +/- 24.0 and + 7.1 +/- 29.7 mg/dl, respectively, p = 0.002), LDL(-10.8 +/- 8.3 vs. -5.7 +/- 21.9 and + 6.8 +/- 28.2 mg/dl, respectively, p = 0.005), and total-/HDL-cholesterol ratio (-0.2 +/- 0.3 vs. -0.1 +/- 0.6 and + 0.2 +/- 0.7 mg/dl, respectively, p = 0.003) in the high-dose vitamin D group compared with low-dose vitamin D and placebo groups. Overall, vitamin D supplementation at a dosage of 4 000 IU/day for 12 weeks in insulin-resistant patients with PCOS had beneficial effects of glucose metabolism and lipid profiles compared with 1 000 IU/day of vitamin D and placebo groups.